Chia C S, Tan W J, Wong J F Sze, Tan G H Ching, Lim C, Wang W, Sin E I-L, Tham C K, Soo K C, Teo M C C
Department of Surgical Oncology, National Cancer Centre Singapore, Singapore.
Department of General Surgery, Singapore General Hospital, Singapore.
Eur J Surg Oncol. 2014 Aug;40(8):909-16. doi: 10.1016/j.ejso.2013.12.028. Epub 2014 Apr 13.
An increasing number of patients are presenting with peritoneal carcinomatosis and more centers are performing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). While morbidity and mortality are shown to be acceptable, quality of life after surgery should be assessed.
63 patients who had CRS and HIPEC from 2001 to 2012 and who were still alive and on follow up were included. The EORTC-QLQ-C30 was administered to the patients.
Median age was 53 years (14-71). 44% had ovarian primaries, 21% had appendicael primaries and 19% had colorectal primaries. Median follow-up was 1.08 years (0.06-9.8). The median time from surgery to the questionnaire was 1.3 years (0.24-10.18). There was no statistical difference in scores when comparing by age, gender, recurrence, gender, PCI score, presence of a complication and type of primary cancer. Scores were highest less than 6 months after surgery, dropped subsequently but rose again after 2 years. Our patients had better scores compared to a control group of outpatient cancer patients at our institution as well as the reference EORTC group.
In keeping with previous quality of life studies done for CRS and HIPEC patients, we have shown that our patients can achieve a good quality of life after CRS and HIPEC even with recurrent disease.
越来越多的患者出现腹膜癌，越来越多的中心开展了细胞减灭术（CRS）和腹腔热灌注化疗（HIPEC）。虽然已证明其发病率和死亡率是可接受的，但术后生活质量仍应评估。
纳入2001年至2012年接受CRS和HIPEC且仍存活并在随访中的63例患者。对患者进行欧洲癌症研究与治疗组织生活质量核心问卷（EORTC-QLQ-C30）测评。
中位年龄为53岁（14 - 71岁）。44%为卵巢原发性肿瘤，21%为阑尾原发性肿瘤，19%为结直肠原发性肿瘤。中位随访时间为1.08年（0.06 - 9.8年）。从手术到问卷调查的中位时间为1.3年（0.24 - 10.18年）。按年龄、性别、复发情况、性别、腹膜癌指数（PCI）评分、是否存在并发症及原发性癌症类型进行比较时，评分无统计学差异。术后不到6个月时评分最高，随后下降，但2年后再次上升。与我院门诊癌症患者对照组以及EORTC参考组相比，我们的患者评分更高。
与之前针对CRS和HIPEC患者进行的生活质量研究一致，我们的研究表明，即使患有复发性疾病，患者在接受CRS和HIPEC后仍可获得良好的生活质量。
